Cannabis Law Report

AUGUST 17, 2021

We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. percent, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial of 24.5 Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. The patent will be issued on January 11, 2022. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax initially focused strictly on pain product candidates.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. The studies are expected to begin in January of 2022. Forward-Looking Statement.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. SCIENTIFIC ACHIEVEMENTS.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52